SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wallace DJ. The clinical presentation of systemic lupus erythematosus. In: WallaceDJ, HahnB, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 62733.
  • 2
    Lahita RG, Bradlow HL, Kunkel HG, Fishman J. Increased 16 alpha hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53: 1748.
  • 3
    Lahita RG, Kunkel HG, Bradlow HL. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 1983; 26: 151721.
  • 4
    Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 2418.
  • 5
    Roubinian J, Talal N, Siiteri PK, Sadakian JA. Sex hormone modulation of autoimmunity in NZB/NZW mice. Arthritis Rheum 1979; 22: 11629.
  • 6
    Melez KA, Boegel WA, Steinberg AD. Therapeutic studies in New Zealand mice. VII. Successful androgen treatment of NZB/NZW F1 females of different ages. Arthritis Rheum 1980; 23: 4147.
  • 7
    Lucas JA, Ahmed SA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Invest 1985; 75: 20913.
  • 8
    Wofsy D, Murphy ED, Roths JB, Dauphinee MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med 1981; 154: 167180.
  • 9
    Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 138892.
  • 10
    Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 26515.
  • 11
    Daynes RA, Dudley DJ, Araneo BA. Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur J Immunol 1990; 20: 793802.
  • 12
    Suzuki T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991; 61: 20211.
  • 13
    Brink I, Thiele B, Burmester GR, Trebeljahr G, Emmrich F, Hiepe F. Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus. Lupus 1999; 8: 72330.
  • 14
    Zietz B, Reber T, Oertel M, Gluck T, Scholmerich J, Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol 2000; 27: 9118.
  • 15
    Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83: 20127.
  • 16
    Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 130510.
  • 17
    Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 182631.
  • 18
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 19
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 20
    Ware J, Snow K, Kosinski M, Gandek B. SF-36 Health Survey manual and interpretation guide. Boston (MA): Nimrod Press; 1993.
  • 21
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 11213.
  • 22
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol 1992; 19: 18201.
  • 23
    Department of Health and Human Services, Food and Drug Administration (FDA). COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. Washington (DC): Food and Drug Administration; 1995.
  • 24
    Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 18018.
  • 25
    Ramsey-Goldman R, Dunn JE, Huang C-F, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 88290.
  • 26
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 9931000.
  • 27
    Orth DN, Kovacs WJ. The adrenal cortex. In: WilsonJD, FosterDW, KronenbergHM, LarsenPR, editors. Williams textbook of endocrinology. 9th ed. Philadelphia: W.B. Saunders; 1998. p. 517664.
  • 28
    Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979; 66: 2105.
  • 29
    Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996; 23: 18916.
  • 30
    Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996; 39: 3708.
  • 31
    Haffner SM, Kushwaha RS, Foster DM, Applebaum-Bowden D, Hazzard WR. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism 1983; 32: 41320.
  • 32
    Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer HB Jr, Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res 1999; 40: 1294303.
  • 33
    Lambert G, Amar MJ, Martin P, Fruchart-Najib J, Foger B, Shamburek RD, et al. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. J Lipid Res 2000; 41: 66772.
  • 34
    Ettinger WH Jr, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988; 37: 10558.
  • 35
    Mease PJ, Merrill JT, Lahita RG, Petri MA, Ginzler EM, Katz RS, et al. GL701 (prasterone, dehydroepiandrosterone) improves systemic lupus erythematosus [abstract]. Arthritis Rheum 2000: 43 Suppl 9: S271.
  • 36
    Chang DM, Lan JL, Luo SF. GL701 (prasterone, dehydroepiandrosterone) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S241.
  • 37
    Yesilova Z, Ozata M, Kocar IH, Turan M, Pekel A, Sengul A, et al. The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2000; 85: 6670.
  • 38
    Falus A, Rokita H, Walcz E, Brozik M, Hidvegi T, Meretey K. Hormonal regulation of complement biosynthesis in human cell lines. II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990; 27: 197201.
  • 39
    Labrie F, Belanger A, Simard J, Van Luu-The, Labrie C. DHEA and peripheral androgen and estrogen formation: intracinology. Ann N Y Acad Sci 1995; 774: 1628.
  • 40
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977; 62: 70714.
  • 41
    Meno-Tetang GML, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J Clin Pharmacol 2001; 41: 1195205.
  • 42
    Hennebold JD, Daynes RA. Regulation of macrophage dehydroepiandrosterone sulfate metabolism by inflammatory cytokines. Endocrinology 1994; 135: 6775.
  • 43
    Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H. Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 1998; 139: 324953.
  • 44
    Padgett DA, Loria RM. Endocrine regulation of murine macrophage function: effects of dehydroepiandrosterone, androstenediol, and androstenetriol. J Neuroimmunol 1998; 84: 618.